202 related articles for article (PubMed ID: 37209119)
21. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
22. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
23. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Pike KA; Tremblay ML
Cytokine; 2016 Jun; 82():52-7. PubMed ID: 26817397
[TBL] [Abstract][Full Text] [Related]
24. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
Lahera A; López-Nieva P; Alarcón H; Marín-Rubio JL; Cobos-Fernández MÁ; Fernández-Navarro P; Fernández AF; Vela-Martín L; Sastre I; Ruiz-García S; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Br J Haematol; 2023 May; 201(4):718-724. PubMed ID: 36786170
[TBL] [Abstract][Full Text] [Related]
25. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
[TBL] [Abstract][Full Text] [Related]
26. Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.
Vicente C; Schwab C; Broux M; Geerdens E; Degryse S; Demeyer S; Lahortiga I; Elliott A; Chilton L; La Starza R; Mecucci C; Vandenberghe P; Goulden N; Vora A; Moorman AV; Soulier J; Harrison CJ; Clappier E; Cools J
Haematologica; 2015 Oct; 100(10):1301-10. PubMed ID: 26206799
[TBL] [Abstract][Full Text] [Related]
27. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
Shouse G; Nikolaenko L
Curr Hematol Malig Rep; 2019 Dec; 14(6):570-576. PubMed ID: 31741284
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis].
Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136
[No Abstract] [Full Text] [Related]
29. JAK/Stat signaling regulates heart precursor diversification in Drosophila.
Johnson AN; Mokalled MH; Haden TN; Olson EN
Development; 2011 Nov; 138(21):4627-38. PubMed ID: 21965617
[TBL] [Abstract][Full Text] [Related]
30. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
31. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
Venugopal S; Bar-Natan M; Mascarenhas JO
Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
Manso R; Sánchez-Beato M; González-Rincón J; Gómez S; Rojo F; Mollejo M; García-Cosio M; Menárguez J; Piris MA; Rodríguez-Pinilla SM
Br J Haematol; 2018 Nov; 183(3):497-501. PubMed ID: 29076126
[No Abstract] [Full Text] [Related]
33. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
34. A robust in vivo model for B cell precursor acute lymphoblastic leukemia.
Fry TJ; Aplan PD
J Clin Invest; 2015 Sep; 125(9):3427-9. PubMed ID: 26301807
[TBL] [Abstract][Full Text] [Related]
35. Tools and methods for studying the Drosophila JAK/STAT pathway.
Chen Q; Giedt M; Tang L; Harrison DA
Methods; 2014 Jun; 68(1):160-72. PubMed ID: 24685392
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
37. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
38. Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.
Fortschegger K; Husa AM; Schinnerl D; Nebral K; Strehl S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299194
[TBL] [Abstract][Full Text] [Related]
39. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.
Pérez C; González-Rincón J; Onaindia A; Almaráz C; García-Díaz N; Pisonero H; Curiel-Olmo S; Gómez S; Cereceda L; Madureira R; Hospital M; Suárez-Massa D; Rodriguez-Peralto JL; Postigo C; Leon-Castillo A; González-Vela C; Martinez N; Ortiz-Romero P; Sánchez-Beato M; Piris MÁ; Vaqué JP
Haematologica; 2015 Nov; 100(11):e450-3. PubMed ID: 26294736
[No Abstract] [Full Text] [Related]
40. Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment.
Nguyen TT; Ramsay L; Ahanfeshar-Adams M; Lajoie M; Schadendorf D; Alain T; Watson IR
Clin Cancer Res; 2021 Jun; 27(12):3432-3442. PubMed ID: 33593882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
